Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Medtronic PLC pages available for free this week:
- Cash Flow Statement
- Common-Size Income Statement
- Analysis of Profitability Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Analysis of Reportable Segments
- Selected Financial Data since 2005
- Net Profit Margin since 2005
- Price to Book Value (P/BV) since 2005
- Price to Sales (P/S) since 2005
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Medtronic PLC for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Long-term Activity Ratios (Summary)
Based on: 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31), 10-K (reporting date: 2020-04-24), 10-Q (reporting date: 2020-01-24), 10-Q (reporting date: 2019-10-25), 10-Q (reporting date: 2019-07-26).
- Net Fixed Asset Turnover
- The net fixed asset turnover ratio shows a declining trend over the observed periods. Starting around 5.99, it gradually decreases through subsequent quarters, reaching approximately 4.88 in the latest period. This trend indicates a gradual reduction in the efficiency of using fixed assets to generate sales. After peaking near 6.13, the ratio steadily declines, suggesting either an increase in net fixed assets that outpaces revenue growth or a reduction in sales attributable to fixed assets over time.
- Total Asset Turnover
- The total asset turnover ratio exhibits a generally stable to slightly upward trend across the timeframe. Initial values near 0.32 dip slightly to around 0.29 but then progressively increase, reaching about 0.38 in the most recent period. This suggests an overall improvement in asset utilization efficiency, with the company managing to generate more sales per unit of total assets as time progresses, especially notable in the latter periods.
- Equity Turnover
- The equity turnover ratio demonstrates a consistent upward trajectory throughout the periods analyzed. Beginning at about 0.57, the ratio modestly increases, culminating near 0.71 by the final period. This upward movement implies enhanced effectiveness in utilizing shareholders' equity to generate revenue, pointing to improved operational efficiency or increased leverage that contributes to higher asset turnover relative to equity.
Net Fixed Asset Turnover
Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | Apr 24, 2020 | Jan 24, 2020 | Oct 25, 2019 | Jul 26, 2019 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||||||
Net sales | |||||||||||||||||||||||||||||||||
Property, plant, and equipment, net | |||||||||||||||||||||||||||||||||
Long-term Activity Ratio | |||||||||||||||||||||||||||||||||
Net fixed asset turnover1 | |||||||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||||||
Net Fixed Asset Turnover, Competitors2 | |||||||||||||||||||||||||||||||||
Abbott Laboratories | |||||||||||||||||||||||||||||||||
Elevance Health Inc. | |||||||||||||||||||||||||||||||||
Intuitive Surgical Inc. | |||||||||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31), 10-K (reporting date: 2020-04-24), 10-Q (reporting date: 2020-01-24), 10-Q (reporting date: 2019-10-25), 10-Q (reporting date: 2019-07-26).
1 Q1 2026 Calculation
Net fixed asset turnover
= (Net salesQ1 2026
+ Net salesQ4 2025
+ Net salesQ3 2025
+ Net salesQ2 2025)
÷ Property, plant, and equipment, net
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The financial data reveals several notable trends over the analyzed periods. Net sales demonstrate fluctuations with periods of both growth and decline. Initially, net sales rose from 7,493 million USD in July 2019 to a peak of approximately 8,188 million USD in April 2021. This was followed by a period of variability, where sales experienced both decreases and increases, with a notable recovery reaching 8,589 million USD in April 2024 before slightly declining again towards the end of the period.
Property, plant, and equipment (PP&E), net, show a consistent upward trend throughout the observed timeline. The net value increased steadily from 4,711 million USD in July 2019 to 7,006 million USD by July 2025. This sustained growth indicates ongoing investment in fixed assets, potentially to support operations and future sales growth.
The net fixed asset turnover ratio, which measures how efficiently the company utilizes its fixed assets to generate sales, shows a clear downward trend starting from April 2020. The ratio decreased from 5.99 to approximately 4.88 by July 2025, signaling a gradual decline in asset efficiency over time. Despite stable or increasing net sales in some periods, the efficiency of using fixed assets to generate revenue is diminishing, possibly reflecting increased asset base growth outpacing sales growth.
- Net Sales
- Experienced growth from mid-2019 until early 2021, followed by fluctuations with a peak in April 2024.
- Periods of decline were interspersed with recoveries indicating variable market or operational conditions.
- Property, Plant, and Equipment (Net)
- Consistently increased over the years, indicating sustained asset investments.
- Growth in PP&E suggests focus on capacity expansion or modernization initiatives.
- Net Fixed Asset Turnover Ratio
- Declined gradually from a high near 6.0 to below 5.0 over the timeframe.
- The decreasing ratio indicates less efficient conversion of assets into sales, suggesting that asset additions may not have proportionally boosted sales revenue.
Total Asset Turnover
Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | Apr 24, 2020 | Jan 24, 2020 | Oct 25, 2019 | Jul 26, 2019 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||||||
Net sales | |||||||||||||||||||||||||||||||||
Total assets | |||||||||||||||||||||||||||||||||
Long-term Activity Ratio | |||||||||||||||||||||||||||||||||
Total asset turnover1 | |||||||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||||||
Total Asset Turnover, Competitors2 | |||||||||||||||||||||||||||||||||
Abbott Laboratories | |||||||||||||||||||||||||||||||||
Elevance Health Inc. | |||||||||||||||||||||||||||||||||
Intuitive Surgical Inc. | |||||||||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31), 10-K (reporting date: 2020-04-24), 10-Q (reporting date: 2020-01-24), 10-Q (reporting date: 2019-10-25), 10-Q (reporting date: 2019-07-26).
1 Q1 2026 Calculation
Total asset turnover
= (Net salesQ1 2026
+ Net salesQ4 2025
+ Net salesQ3 2025
+ Net salesQ2 2025)
÷ Total assets
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The financial data over the quarters indicate several notable trends and developments in the company's performance. Analysis of net sales, total assets, and total asset turnover ratios over the periods provides insight into the operational efficiency and asset management of the business.
- Net Sales
- Net sales exhibit a fluctuating but generally positive trend over the observed quarters. Starting from approximately 7,493 million USD in mid-2019, sales experienced some variability with a notable dip during the first quarter of 2020, coinciding with 5,997 million USD, possibly reflecting external market disturbances. Subsequently, sales recovered and showed an increasing trend reaching a peak at 8,589 million USD around early 2024. However, there are intermittent declines visible throughout the post-2020 period, indicating some cyclicality or market pressure affecting revenue generation. Overall, the recovery and eventual growth in net sales suggest resilience and an improving demand environment.
- Total Assets
- Total assets held by the company reveal a generally stable to slightly declining pattern over the periods. The asset base began near 91,268 million USD in mid-2019 and fluctuated around the 90,000 to 94,000 million USD range during the years that followed. Notably, there is a small downward trend observable into 2024, with assets marginally decreasing towards the 90,972 million USD mark by mid-2025. This indicates relatively consistent asset levels, with no significant expansion or contraction, suggesting controlled capital investment and asset management practices.
- Total Asset Turnover Ratio
- The total asset turnover ratio, which measures the efficiency of using assets to generate sales, shows a clear upward trajectory starting from 0.32 in early 2020 and gradually rising to 0.38 by mid-2025. The initial quarter data is missing, but available figures from 2020 onward display a consistent increase in turnover efficiency. This improvement implies the company is generating more sales per unit of asset over time, reflecting enhanced operational performance and possibly better utilization of fixed and current assets. The increase from 0.29-0.32 range to 0.37-0.38 toward the end of the period is a positive sign of more effective asset deployment.
In summary, while net sales demonstrate some volatility, the overall trajectory is upward with notable recovery and growth after early declines. The total asset base remains stable with slight decreases toward the end of the period, indicating measured asset control. Most importantly, the steady improvement in the total asset turnover ratio highlights increasing operational efficiency, signaling that the company is generating higher revenue from its assets over time. These combined trends suggest a favorable shift toward more effective resource use and a strengthening financial performance framework.
Equity Turnover
Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | Apr 24, 2020 | Jan 24, 2020 | Oct 25, 2019 | Jul 26, 2019 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||||||
Net sales | |||||||||||||||||||||||||||||||||
Shareholders’ equity | |||||||||||||||||||||||||||||||||
Long-term Activity Ratio | |||||||||||||||||||||||||||||||||
Equity turnover1 | |||||||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||||||
Equity Turnover, Competitors2 | |||||||||||||||||||||||||||||||||
Abbott Laboratories | |||||||||||||||||||||||||||||||||
Elevance Health Inc. | |||||||||||||||||||||||||||||||||
Intuitive Surgical Inc. | |||||||||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31), 10-K (reporting date: 2020-04-24), 10-Q (reporting date: 2020-01-24), 10-Q (reporting date: 2019-10-25), 10-Q (reporting date: 2019-07-26).
1 Q1 2026 Calculation
Equity turnover
= (Net salesQ1 2026
+ Net salesQ4 2025
+ Net salesQ3 2025
+ Net salesQ2 2025)
÷ Shareholders’ equity
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals several notable trends in net sales, shareholders’ equity, and equity turnover ratios over the periods observed.
- Net Sales
- Net sales exhibit fluctuations across the quarters with some periods showing declines while others register increases. Initially, net sales were approximately $7,493 million in mid-2019 and increased modestly to near $7,717 million by the beginning of 2020. A decline occurred in the second quarter of 2020, dropping to $5,997 million, likely reflecting external challenges affecting sales volumes or market demand.
- Post the mid-2020 dip, there was a recovery and gradual growth with net sales reaching a peak of $8,589 million by early 2024. This suggests an overall positive recovery trajectory despite periodic volatility. The data from 2023 to mid-2025 reflects sustained strength, although some quarter-to-quarter variations remain evident.
- Shareholders’ Equity
- Shareholders’ equity displayed relative stability from mid-2019 to early 2022, fluctuating between approximately $50,296 million and $52,672 million. However, from 2023 onward, a gradual declining trend emerges. By mid-2025, shareholders’ equity descends to around $47,893 million, indicating a reduction in net assets or accumulated equity over this latter period.
- This downward tendency could imply increased liabilities, share repurchases, dividend distributions, or other equity-reducing activities, warranting further detailed investigation into the balance sheet components and corporate actions during this period.
- Equity Turnover Ratio
- The equity turnover ratio, which measures net sales relative to shareholders’ equity, starts at approximately 0.57 in mid-2020 and shows a generally increasing trend over subsequent quarters. By mid-2025, the ratio reaches around 0.71.
- This upward trajectory indicates improved efficiency in utilizing equity to generate sales. Despite the decline in shareholders’ equity during later periods, net sales growth has supported stronger turnover ratios, reflecting enhanced operational leverage or asset utilization efficiency.
In summary, the company experienced sales volatility early in the pandemic period, followed by recovery and growth. While equity levels have diminished somewhat in recent years, operational efficiency concerning equity use has improved, as indicated by rising equity turnover ratios. These mixed trends suggest an evolving financial position with strengths in sales performance tempered by decreasing equity base, highlighting areas for strategic focus.